167 related articles for article (PubMed ID: 12506018)
1. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO.
Chagraoui H; Tulliez M; Smayra T; Komura E; Giraudier S; Yun T; Lassau N; Vainchenker W; Wendling F
Blood; 2003 Apr; 101(8):2983-9. PubMed ID: 12506018
[TBL] [Abstract][Full Text] [Related]
2. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation.
Yan XQ; Lacey D; Hill D; Chen Y; Fletcher F; Hawley RG; McNiece IK
Blood; 1996 Jul; 88(2):402-9. PubMed ID: 8695786
[TBL] [Abstract][Full Text] [Related]
3. Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG).
Wang JC; Hemavathy K; Charles W; Zhang H; Dua PK; Novetsky AD; Chang T; Wong C; Jabara M
Exp Hematol; 2004 Oct; 32(10):905-10. PubMed ID: 15504545
[TBL] [Abstract][Full Text] [Related]
4. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis.
Kakumitsu H; Kamezaki K; Shimoda K; Karube K; Haro T; Numata A; Shide K; Matsuda T; Oshima K; Harada M
Leuk Res; 2005 Jul; 29(7):761-9. PubMed ID: 15927672
[TBL] [Abstract][Full Text] [Related]
5. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice.
Chagraoui H; Komura E; Tulliez M; Giraudier S; Vainchenker W; Wendling F
Blood; 2002 Nov; 100(10):3495-503. PubMed ID: 12393681
[TBL] [Abstract][Full Text] [Related]
6. Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin.
Bock O; Loch G; Schade U; Büsche G; Wasielewski R; Wiese B; Kreipe H
Br J Haematol; 2005 Jul; 130(1):76-82. PubMed ID: 15982347
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
8. Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin.
Wagner-Ballon O; Chagraoui H; Prina E; Tulliez M; Milon G; Raslova H; Villeval JL; Vainchenker W; Giraudier S
J Immunol; 2006 Jun; 176(11):6425-33. PubMed ID: 16709799
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
[TBL] [Abstract][Full Text] [Related]
10. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.
Suda K; Udagawa N; Sato N; Takami M; Itoh K; Woo JT; Takahashi N; Nagai K
J Immunol; 2004 Feb; 172(4):2504-10. PubMed ID: 14764723
[TBL] [Abstract][Full Text] [Related]
11. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects.
Thirunavukkarasu K; Miles RR; Halladay DL; Yang X; Galvin RJ; Chandrasekhar S; Martin TJ; Onyia JE
J Biol Chem; 2001 Sep; 276(39):36241-50. PubMed ID: 11451955
[TBL] [Abstract][Full Text] [Related]
12. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function.
Yun TJ; Tallquist MD; Aicher A; Rafferty KL; Marshall AJ; Moon JJ; Ewings ME; Mohaupt M; Herring SW; Clark EA
J Immunol; 2001 Feb; 166(3):1482-91. PubMed ID: 11160187
[TBL] [Abstract][Full Text] [Related]
13. Expression of osteoprotegerin mRNA and protein in murine megakaryocytes.
Chagraoui H; Sabri S; Capron C; Villeval JL; Vainchenker W; Wendling F
Exp Hematol; 2003 Nov; 31(11):1081-8. PubMed ID: 14585373
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats.
Wang FS; Wang CJ; Chen YJ; Huang YT; Huang HC; Chang PR; Sun YC; Yang KD
Endocrinology; 2004 May; 145(5):2148-56. PubMed ID: 14962990
[TBL] [Abstract][Full Text] [Related]
15. Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice.
Oshiro T; Shiotani A; Shibasaki Y; Sasaki T
Anat Rec; 2002 Apr; 266(4):218-25. PubMed ID: 11920384
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss.
Zehnder AF; Kristiansen AG; Adams JC; Kujawa SG; Merchant SN; McKenna MJ
Laryngoscope; 2006 Feb; 116(2):201-6. PubMed ID: 16467704
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.
Kostenuik PJ; Shalhoub V
Curr Pharm Des; 2001 May; 7(8):613-35. PubMed ID: 11375772
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.
Min H; Morony S; Sarosi I; Dunstan CR; Capparelli C; Scully S; Van G; Kaufman S; Kostenuik PJ; Lacey DL; Boyle WJ; Simonet WS
J Exp Med; 2000 Aug; 192(4):463-74. PubMed ID: 10952716
[TBL] [Abstract][Full Text] [Related]
19. Cyclical tensile force on periodontal ligament cells inhibits osteoclastogenesis through OPG induction.
Kanzaki H; Chiba M; Sato A; Miyagawa A; Arai K; Nukatsuka S; Mitani H
J Dent Res; 2006 May; 85(5):457-62. PubMed ID: 16632761
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
